Cargando…
Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation
Buprenorphine-naloxone (BUP-NX) is a lifesaving treatment for opioid use disorder. The increasing use of illicitly manufactured fentanyl, however, has made initiating BUP-NX more likely to precipitate withdrawal—an experience that deters treatment and causes return to use. If BUP-NX cannot be succes...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022654/ https://www.ncbi.nlm.nih.gov/pubmed/36149001 http://dx.doi.org/10.1097/ADM.0000000000001073 |
_version_ | 1784908766915854336 |
---|---|
author | Randall, Adam Hull, Ilana Martin, Stephen A. |
author_facet | Randall, Adam Hull, Ilana Martin, Stephen A. |
author_sort | Randall, Adam |
collection | PubMed |
description | Buprenorphine-naloxone (BUP-NX) is a lifesaving treatment for opioid use disorder. The increasing use of illicitly manufactured fentanyl, however, has made initiating BUP-NX more likely to precipitate withdrawal—an experience that deters treatment and causes return to use. If BUP-NX cannot be successfully started, it cannot work. We describe the case of a patient who was able to transition to a therapeutic dose of BUP-NX less than 3 hours after his last illicitly manufactured fentanyl use by choosing to self-administer intranasal naloxone. After the naloxone, the transition took 31 minutes, including 14 minutes of expected moderately severe withdrawal. He remains in care with BUP-NX and would recommend this transition approach to others. |
format | Online Article Text |
id | pubmed-10022654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-100226542023-03-18 Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation Randall, Adam Hull, Ilana Martin, Stephen A. J Addict Med Case Reports Buprenorphine-naloxone (BUP-NX) is a lifesaving treatment for opioid use disorder. The increasing use of illicitly manufactured fentanyl, however, has made initiating BUP-NX more likely to precipitate withdrawal—an experience that deters treatment and causes return to use. If BUP-NX cannot be successfully started, it cannot work. We describe the case of a patient who was able to transition to a therapeutic dose of BUP-NX less than 3 hours after his last illicitly manufactured fentanyl use by choosing to self-administer intranasal naloxone. After the naloxone, the transition took 31 minutes, including 14 minutes of expected moderately severe withdrawal. He remains in care with BUP-NX and would recommend this transition approach to others. Lippincott Williams & Wilkins 2023 2022-09-22 /pmc/articles/PMC10022654/ /pubmed/36149001 http://dx.doi.org/10.1097/ADM.0000000000001073 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Addiction Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Case Reports Randall, Adam Hull, Ilana Martin, Stephen A. Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation |
title | Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation |
title_full | Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation |
title_fullStr | Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation |
title_full_unstemmed | Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation |
title_short | Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation |
title_sort | enhancing patient choice: using self-administered intranasal naloxone for novel rapid buprenorphine initiation |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022654/ https://www.ncbi.nlm.nih.gov/pubmed/36149001 http://dx.doi.org/10.1097/ADM.0000000000001073 |
work_keys_str_mv | AT randalladam enhancingpatientchoiceusingselfadministeredintranasalnaloxonefornovelrapidbuprenorphineinitiation AT hullilana enhancingpatientchoiceusingselfadministeredintranasalnaloxonefornovelrapidbuprenorphineinitiation AT martinstephena enhancingpatientchoiceusingselfadministeredintranasalnaloxonefornovelrapidbuprenorphineinitiation |